



Published in final edited form as:

Annu Rev Public Health. 2009 April 29; 30: 107–122. doi:10.1146/annurev.publhealth.031308.100143.

Health Effects of Arsenic and Chromium in Drinking Water: Recent Human Findings

Allan H. Smith and Craig M. Steinmaus

School of Public Health, University of California, Berkeley, California 94720; email: ahsmith@berkeley.edu, craigs@berkeley.edu

Abstract

Even at high concentrations, arsenic-contaminated water is translucent, tasteless, and odorless. Yet almost every day, studies report a continually increasing plethora of toxic effects that have manifested in exposed populations throughout the world. In this article we focus on recent findings, in particular those associated with major contributions since 2006. Early life exposure, both in utero and in childhood, has been receiving increased attention, and remarkable increases in consequent mortality in young adults have been reported. New studies address the dose-response relationship between drinking-water arsenic concentrations and skin lesions, and new findings have emerged concerning arsenic and cardiovascular disease. We also review the increasing epidemiological evidence that the first step of methylation of inorganic arsenic to monomethylated arsenic (MMA) is actually an activation step rather than the first step in detoxification, as once thought. Hexavalent chromium differs from arsenic in that it discolors water, turning the water yellow at high concentrations. A controversial issue is whether chromium causes cancer when ingested. A recent publication supports the original findings in China of increased cancer mortality in a population where well water turned yellow with chromium.

Keywords

early life exposure; skin lesions; childhood cancer; methylation

INTRODUCTION

Arsenic is classified as a metalloid and chromium a metal, but they do have some properties in common. Inhalation of inorganic arsenic and inhalation of hexavalent chromium each cause lung cancer in smelter workers (21,39). They also share a peculiar property in that each may cause lung cancer following ingestion via drinking water. However, they differ in that the evidence regarding inorganic arsenic in drinking water is extensive and sufficient for it to be established by the International Agency for Research on Cancer (IARC) as a Group 1 carcinogen. In contrast, the human evidence for hexavalent chromium is limited largely to one population study in China.

Arsenic and chromium have another feature in common. Entering each into PubMed retrieves more than 6000 publications in the past 10 years, which is daunting when trying to write a review on even one of them. We have therefore limited our review to topics in which there have been important new health findings presented in epidemiological studies published since

Copyright © 2009 by Annual Reviews. All rights reserved

DISCLOSURE STATEMENT The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.

2006. Even with this restriction, an exhaustive assessment was not possible, so we have further restricted ourselves to selected major topics concerning arsenic in drinking water and one important topic concerning hexavalent chromium in drinking water. We identified new studies published since 2006 on each of these topics and review earlier publications when they are on the same topic.

ARSENIC

Effects of Early Life Exposure to Arsenic

The potential for arsenic in drinking water to cause effects in utero and for early life exposures to affect child development, child health, and adult disease has been a topic of increasing attention in recent years (76). Table 1 presents the findings from epidemiological studies contributing information on these topics.

Pregnancy Outcomes

The main findings concerning pregnancy outcomes relate to spontaneous abortion, stillbirths, reduced birth weight, and infant mortality (Table 1). Studies have produced mixed findings.

Fetal Loss

Fetal loss includes spontaneous abortions (loss up to 28 weeks of pregnancy) and stillbirths (loss after 28 weeks). Increased fetal loss was reported in some studies but not others (Table 1). Differences are apparent in studies of the affected populations in Bangladesh and adjacent West Bengal, India. Ahmad et al. (2) present data for 96 exposed women ($>50 \mu\text{g/L}$) compared with 96 nonexposed women ($<20 \mu\text{g/L}$). The relative risk (RR) can be estimated at 2.9 ($p = 0.008$) for spontaneous abortion and 2.2 ($p = 0.046$) for stillbirths. Similar estimates were found in a study by Milton et al. (51) involving 533 women: spontaneous abortion RR = 2.5 (95% CI 1.5--4.3) and stillbirth RR = 2.5 (95% CI 1.3--4.9). In contrast, von Ehrenstein et al. (78), who studied 202 (?not 660) pregnancies, did not find increased risks of spontaneous abortion (RR = 1.0, CI: 0.4--2.7), but reported increased stillbirths above $200 \mu\text{g/L}$ (RR = 6.1, CI: 1.5--24), especially for 12 women who had arsenic skin lesions (RR = 13.1, CI: 3.2--54). Kwok et al. (37) studied outcomes for 2006 pregnant women and found no increase in stillbirths (they did not investigate spontaneous abortions). One can estimate from data they present that, among 732 women with arsenic exposure above $200 \mu\text{g/L}$, there were 20 stillbirths, whereas among 556 low-exposure women ($<50 \mu\text{g/L}$) there were 13 stillbirths (RR = 1.17, $p = 0.33$).

By far the largest study, which also had the advantage of being a population-based cohort study, reported outcomes of 29,134 pregnancies in Matlab, Bangladesh (60). Results were not separated by spontaneous abortions and stillbirths, but the RR estimate for fetal loss was 1.14 (95% CI 1.04--1.25) for exposure above $50 \mu\text{g/L}$. The fetal loss relative risk estimate for the 5,607 pregnancies in the highest exposure category ($>409 \mu\text{g/L}$ during pregnancy) was only 1.10 (95% CI 0.97--1.25). In summary, these studies have yielded conflicting findings. The Matlab study involving 29,134 pregnancies is 10 times larger than any other study and found negligible evidence of increased risk. Coupled with a lack of increased risk demonstrated in the second largest study (37), the evidence that arsenic in drinking water increases the risk of fetal loss is limited. The conflicting findings from the smaller studies are thus puzzling.

Reduced Birth Weight and Infant Mortality

Reductions in birth weight have been found in a low-arsenic-exposure study in Chile ($<50 \mu\text{g/L}$) (28), and in higher-exposure studies in Taiwan (86) and in Bangladesh (34). In the low-exposure study in Chile, the reduction in average birth weight estimate was 57 g, in Taiwan 30 g, and in Bangladesh one can derive from the regression coefficients that an increase in $1 \mu\text{g/g}$ in hair arsenic was associated with a 193.5-g reduction in birth weight.

Infant mortality was reported by Hopenhayn et al. 2000, Rahman et al. 2007, and von Ehrenstein et al. 2006 (29,60,78). The largest study (60) involved 29,134 pregnancies and reported a relative risk estimate of 1.17 (CI: 1.02--1.32) for infant mortality.

Child Cognitive Function

The first study that reported effects of arsenic in drinking water on cognitive function was conducted in Thailand (63). Data were collected from 529 children ages 6--9 years, and arsenic exposure (based on hair concentrations) was associated with reduced visual perception test scores ($p = 0.01$). A study of 49 exposed children and 60 unexposed children in Taiwan reported reduced pattern memory and switching attention scores ($p < 0.01$) with arsenic concentrations in water that averaged 185 $\mu\text{g/L}$ in the high-exposure group (72). This result was followed by a study of 201 children in Bangladesh, which reported reduced intellectual function tests for exposures above 50 $\mu\text{g/L}$ of arsenic in water, particularly in performance and full-scale scores ($p < 0.01$) (83). The associations were stronger for well-water arsenic concentrations than for urinary arsenic concentrations. Finally, in a study of 351 children in India, von Ehrenstein et al. (79) reported reduced vocabulary test scores, reduced object assembly scores, and reduced picture completion scores ($p = 0.02$) associated with urine concentrations of arsenic but not with the histories of arsenic water concentrations.

These studies of cognitive function in children each suggest some effects related to arsenic. The findings are difficult to compare because of differences in test instruments used or differences in assembling and reporting findings. The two most recent studies are distinctly different in that one finds an association with arsenic water concentrations but not with urine arsenic concentrations (83), whereas the other study found a relationship only with urine arsenic concentrations (79). In summary, although these studies suggest that arsenic does produce some effects on intellectual development in children, the inconsistencies in the findings suggest that further studies are needed to confirm and clarify the effects.

Childhood Cancer

Limited information has been documented on arsenic exposure in drinking water and the incidence of childhood cancer. Infant-Rivard et al. (35) reported a relative risk estimate for lymphoblastic leukemia of 1.39 (CI: 0.7--2.76); however, the arsenic concentrations in drinking water were very low, so no increase could be expected. Moore et al. (52) studied childhood cancer incidence rates in Nevada at higher water concentrations, up to concentrations in the range of 35--90 $\mu\text{g/L}$. For all childhood cancer combined, the RR estimate in the high-exposure category was 1.25 (CI 0.91--1.69), and 1.37 (CI: 0.92--1.83) for leukemia.

Childhood cancer and much higher water arsenic concentrations in Northern Chile, up to 860 $\mu\text{g/L}$, were studied by Liaw et al. (40). No increases were detected for all cancers combined. However, childhood liver cancer mortality under age 20, which is normally extremely rare, was markedly increased for those who were young children when they would have experienced high water arsenic concentrations (RR = 10.6, 95% CI 2.9--39.2, $p < 0.001$). These children all died before 1980 and medical records could not be located for histological confirmation, nor could individual exposure be confirmed. In summary, the evidence to date does not support an overall increase in mortality from childhood cancers, but one study has found high relative risks for liver cancer associated with high water arsenic concentrations.

Adult Disease Following Early Life Exposure

Smith et al. (65) reported that 10 individuals ages 30--39 (0.8 expected) died in northern Chile from chronic obstructive pulmonary disease (COPD) in the years 1989--1993, and these individuals would have been young children during the peak arsenic exposure period. Lung cancer relative risk estimates were also elevated in this age range (14 men observed, 1.2

expected; 5 women observed, 1.2 expected). Mortality in the same population in northern Chile was further studied up to the year 2000, and investigators found that the cause of the increased COPD mortality rate was bronchiectasis. For the birth cohort born just before the high-exposure period (1950--1957), and exposed in early childhood, the standardized mortality ratio (SMR) for lung cancer was 7.0 (CI 5.4--8.9, $p < 0.001$) and the SMR for bronchiectasis was 12.4 (CI 3.3--31.7, $p < 0.001$). For those born during the high-exposure period (1958--1971), with probable exposure in utero and in early childhood, the corresponding SMRs were 6.1 (CI 3.5--9.9, $p < 0.001$) for lung cancer, and 46.2 (CI 21.1--87.7, $p < 0.001$) for bronchiectasis. They noted that the magnitude of the effects found on lung cancer and bronchiectasis mortality has no parallel when compared to effects of other environmental exposures occurring in utero and/or in early childhood.

Biological plausibility for the cancer findings can be found in experiments conducted in mice (80,81). The offspring of pregnant mice who were given high doses of arsenic in their drinking water developed tumors at multiple sites, including the lung in female offspring, with incidence of lung carcinoma increased to 5/24 (21%) compared with 0/25 (0%) in the unexposed controls.

Mortality from acute myocardial infarction was also assessed in northern Chile, and studies showed that mortality increased soon after high exposures started (88). Of particular interest was the fact that the highest relative risk estimates were for young adult men ages 30--49 who were born in the high-exposure period, with probable exposure in utero and in early childhood (RR = 3.2., 95% CI: 2.79--3.75, $p < 0.001$). Atherosclerosis has been induced in mice by in utero exposure (66a).

In contrast to these marked increased mortality risks following early life exposure to arsenic in drinking water, Rahman et al. 2006 (61) and Lindberg et al. 2008 (41) reported reduced risks of arsenic-induced skin lesions in Bangladesh in those exposed since infancy, compared with those exposed only later in life. For example, the relative risk estimate for those starting to drink tubewell water at ages 1--17, compared with those who started the year they were born, was 4.0 (CI: 2.5--6.2) (41). For a variety of reasons, assessing exposures many years in the past (i.e., exposures in infancy) is difficult, and misclassification of past exposure is likely. If misclassification was greater for exposures in the distant past (i.e., those in infancy) than exposures that were more recent (i.e., those later in life), risks could spuriously appear to be greater in those who have experienced only later life exposure compared with those exposed early in life. No information is provided in these studies to assess the accuracy of distant past or infant exposures.

In summary, studies in one exposed population in Chile provide evidence for marked increase in adult mortality from lung cancer, bronchiectasis, and myocardial infarction following early life exposure. These findings need to be confirmed in other populations. One study reports lower risk of skin lesions with arsenic exposure in infancy compared with those whose exposure started later.

Concentrations of Arsenic in Drinking Water and Skin Alterations

Arsenic ingestion causes characteristic pigmentation changes in the skin of the trunk and limbs and nodular keratosis on the palms and soles. In most populations with arsenic water problems, lesions are the first sign to indicate the problem. Skin lesions were identified in connection with arsenic in drinking water in Taiwan in the 1960s (74) and in West Bengal, India, in the 1980s (10). An important current issue is whether skin lesions occur soon after exposure first begins and are caused by relatively low arsenic exposures. If they are, then skin lesions could perhaps serve as a sentinel event for arsenic problems that require public health intervention. However, if they are not, then priority would need to be given to performing extensive arsenic

testing in all groundwater sources used for drinking, even in populations where arsenic-caused skin lesions are not evident.

Table 2 presents the findings from studies that identify the prevalence of skin lesions in relation to concentrations of arsenic in drinking water. As shown in this table, several studies have reported skin lesions in subjects in whom the highest known arsenic exposure was below 50 $\mu\text{g/L}$. A superficial reading of these data could suggest to the unwary that skin lesions occur at very low water arsenic concentrations. Most of these studies, however, involved cross-sectional ascertainment of exposure, and no data are given concerning missing exposure information, including the possibility of high exposures in the distant past. In India and Bangladesh (where all the studies linking low exposures to skin lesions have been done), individuals generally obtain water from multiple sources over their lifetimes, and incomplete or missing data are inevitable. In addition, even when past water source histories are obtained, previously used tubewells may be closed or broken at the time of cross-sectional study investigations. So far, only one study has focused on participants investigators thought had provided complete exposure data for the previous 20 years (26). This study, in West Bengal, India, originally began as a cross-sectional survey of 7683 participants, including 361 with pigmentation changes and 156 with keratosis (25). In the original report, 12 with skin lesions had been consuming water containing less than 50 $\mu\text{g/L}$ of arsenic. At the time, however, the authors noted that “more detailed exposure assessment and measurement of all past and present water arsenic levels may show that those thought to be consuming low arsenic water may actually have been more heavily exposed from other sources.” (25) After completing such an investigation, producing detailed information on past exposure for more than 20+ years, the same group found that all individuals confirmed to have had skin lesions as well as complete water source histories had consumed water containing arsenic at concentrations higher than 100 $\mu\text{g/L}$ at some point in time, and the large majority had consumed water containing arsenic concentrations higher than 200 $\mu\text{g/L}$ (26). In addition, this study also reported that the average latency for skin lesions was 23 years from first exposure. The data from this study suggests that arsenic exposures well above 100 $\mu\text{g/L}$ (and most likely above 200 $\mu\text{g/L}$) are needed to cause skin lesions. These data also highlight the need for investigators to focus on those subjects with complete information on past water sources and past exposure. Many, if not all, of the studies in Table 2 likely included subjects with incomplete past exposure information. These studies could have missed past periods of high exposure in some skin lesion subjects and therefore could have reported incorrect evidence linking skin lesions with low arsenic exposure. In summary, the Haque et al. study, the only one focusing on subjects with complete past exposure information, provides evidence that cases of skin lesions caused by arsenic rarely occur when arsenic water concentrations are lower than 200 $\mu\text{g/L}$. Implementation of drinking water standards should be based on the risks of other more serious diseases or diseases that may occur at exposures below 200 $\mu\text{g/L}$.

Cardiovascular Disease

A large number of studies have considered cardiovascular effects of arsenic in drinking water, especially in Taiwan (20,56,82). Here we focus our attention on publications appearing in the literature since 2006. The major epidemiological studies are listed in Table 3. Ahmad et al. (1) in Bangladesh and Mumford et al. (54) in a study in China reported similar electrocardiogram changes in exposed populations, which included changes associated with increased risk of arrhythmia and mortality. Chen et al. (11) in Bangladesh and Kwok et al. (38) in China reported blood pressure changes, suggesting potential increased risk for both cardiovascular and cerebrovascular disease.

A report of increased carotid atherosclerosis correlating with arsenic exposure in Taiwan further supported evidence linking cerebrovascular disease and arsenic exposure (85), and

some evidence, also in Taiwan, documented that small increases in intracerebral hemorrhage mortality decreased after reducing arsenic exposure (50). A clear latency pattern was found between myocardial infarction mortality and exposure to arsenic in drinking water in Chile (88), supplementing the latency findings concerning lung cancer and bladder cancer (46). However, there was no evidence of increased cerebrovascular mortality despite high arsenic exposures affecting a large population living in northern Chile (88).

In summary, mounting evidence supports that arsenic in drinking water causes increased risks of coronary artery disease, including increased mortality, but the evidence concerning cerebrovascular disease is mixed.

Evidence that Arsenic Methylation Increases Disease Risks

Susceptibility to the health effects of arsenic appears to vary from person to person, and a wide variety of factors including age of exposure, genetics, diet, and concurrent exposures such as smoking can impact the degree of severity of those effects. The results of several previous studies have shown that interindividual differences in arsenic metabolism may be responsible for a substantial portion of these susceptibility differences. The primary metabolic pathway of ingested inorganic arsenic in humans is methylation (75). Once ingested, InAs is methylated to monomethylarsonic acid (MMA5), which is reduced to monomethylarsonous acid (MMA3). MMA3 is then methylated to dimethylarsinic acid (DMA5), which is reduced to dimethylarsinous acid (DMA3). In humans, this process is not complete, and some arsenic remains as InAs and MMA. In humans, arsenic is eliminated primarily via urinary excretion, and the relative distribution of InAs, MMA, and DMA in urine reflects internal metabolism (44,45). As such, the proportions of InAs, MMA, and DMA excreted in urine have been commonly used as biomarkers of the degree to which individuals methylate ingested InAs (55). Ingested InAs is typically excreted as 10%--20% InAs, 10%--15% MMA, and 60%--75% DMA, although large interindividual variations exist (30).

DMA3: dimethylarsinous acid

MMA3: monomethylarsonous acid

Until recently, methylation of InAs was thought to be primarily a detoxification pathway because the methylated species most commonly measured in human urine samples, MMA and DMA, are more readily excreted and thought to be less toxic than InAs (9,23,53). **MMA3** and **DMA3** are highly unstable in human urine and therefore have been measured in only a few human studies. However, MMA3 is generally much more toxic *in vitro* than is its pentavalent form, and it is even more toxic than trivalent InAs (18,47,57,70). These findings have led to the hypothesis that MMA3 may be the primary toxic species of ingested arsenic.

Several studies have investigated the relationship between interindividual differences in arsenic metabolism and risks of arsenic-related disease. These studies have investigated risks in subjects who excrete high or low proportions of each of the three major arsenic species (InAs, MMA, DMA) in their urine. Figure 1 and Table 4 show the results of studies comparing the risks of various arsenic-related disease end points in those who excrete high and low proportions of arsenic as MMA [MMA/(InAs + MMA + DMA) or %MMA]. In most studies, adjustments were made for total arsenic intake, typically either by adjusting for cumulative arsenic exposure (CAE) in the analysis or by stratifying subjects into high and low CAE groups. In several of the Taiwan studies, results are for the MMA/DMA ratio rather than for the % MMA. Because 60%--75% of arsenic in urine is in the form of DMA, the ratio MMA/DMA is closely related to %MMA. In some of the study results shown in Figure 1, the reference group (OR = 1.0) is the group with low %MMA. In other studies, data were stratified by CAE, and the reference groups are those subjects with low CAE and low %MMA. For these studies, only data from the high-CAE strata are shown.

As a whole, the studies in Figure 1 and Table 4 provide a consistent body of evidence that interindividual differences in arsenic metabolism, specifically the proportion of arsenic excreted as MMA, is associated with susceptibility to arsenic-related disease. In all but one study, odds ratios for the various diseases are ~1.5-4 times greater in subjects with higher % MMA compared with those with lower % MMA. The one exception is the study of hypertension by Huang et al., where adjusted odds ratios in the low and high % MMA group were essentially no different (1.00 and 1.04, respectively).

Several biases could have affected the studies shown in Figure 1, but are unlikely to have caused the positive differences identified. In most of the studies, only a single urine sample was collected from each subject, and this sample was collected at or near the time of disease diagnosis. The latency period of several arsenic-caused diseases such as cancer may be several decades or more, which calls to question the validity of using a recent assessment of methylation to estimate past methylation patterns. Methylation patterns remain fairly stable over periods of time of up to a year (17,69), but intraindividual variability over time does exist and could have led to some misclassification of %MMA. However, because samples were collected, stored, and analyzed independently of disease status, these factors would most likely have had nondifferential effects and biased results toward the null, not toward the positive effects identified in Figure 1. The assessment of methylation near or after disease diagnosis also raises concerns about the temporal relationship between disease and methylation capacity. That is, the effects seen in these studies might not be due to the impact of methylation patterns on disease, but rather to the impact of disease or disease treatment on methylation patterns. However, five of the studies presented in Figure 1 involved nonmelanoma skin cancer or skin lesions. Another study has reported an association between %MMA and the presence of chromosomal aberrations in lymphocytes (43). These conditions are generally benign and would not be expected to cause the major systemic metabolic changes that can be caused by more fatal diseases. Identifying associations in studies involving these relatively benign conditions suggests that the results shown in Figure 1 were not due to the impact of disease on methylation capacity.

As discussed above, evidence increasingly demonstrates that MMA3 is much more toxic than its pentavalent form and is more toxic than InAs or DMA. All the studies given in Figure 1 involve both valence forms of MMA combined (MMA3 + MMA5). Because MMA3 is highly unstable in urine and rapidly oxidized to MMA5, isolating MMA3 and separating its effects from those of MMA5 is very difficult in field investigations. Only one study has assessed the role of MMA3 in an arsenic-related disease in humans. (This study did not present odds ratios so was not included in Figure 1). In this study, in an arsenic-exposed region in Mexico, % MMA3 levels were higher in subjects with arsenic-caused skin lesions (mean %MMA3 = 7.7%, $n = 55$) than in exposed subjects without skin lesions (mean %MMA3 = 5.9%, $n = 21$, $p = 0.072$) (77). Using *in vitro* assays, it is plausible that MMA3 is the primary toxic species responsible for the effects seen in Figure 1, and the total MMA (MMA3 + MMA5) measured in these studies is simply a marker for MMA3. Investigators do not currently know how well total MMA accurately reflects MMA3. However, total MMA is likely not a perfect measure of MMA3, and a less-than-perfect correlation would result in nondifferential misclassification of %MMA3. This misclassification would bias odds ratios truly related to %MMA3 toward the null. Thus, if MMA3 really is the primary toxic agent, the difference in odds ratios due to interindividual differences in methylation capacity would likely be even greater than the 1.5 to 4-fold differences shown in Figure 1.

In summary, almost all studies of arsenic metabolism and arsenic-related health effects have shown that people who excrete elevated proportions of MMA have higher risks of arsenic-caused cancer and other arsenic-related health effects than do those who excrete lower proportions. Although some studies involve relatively small numbers of subjects, the

consistency of these findings---across different studies, different health effects, different countries, different researchers, and different study populations---supports the hypothesis that individual differences in arsenic methylation patterns may play an important role in susceptibility to arsenic-related disease. Future research is also needed to ascertain which factors control %MMA in humans. Several demographic (e.g., gender and age), dietary (e.g., folate and selenium), and genetic factors have been linked to arsenic metabolism in humans, but these have generally accounted for only a small amount of the total interindividual variability in the metabolic process (16,22,55,68).

CHROMIUM

In contrast with arsenic, not much that is new has appeared in the epidemiological literature since 2006. An important exception to this are findings concerning chromium ingestion and cancer. Like arsenic, it has long been established that inhalation of chromium, in particular hexavalent chromium (CrVI), can cause human lung cancer (36). But could chromium also cause cancer following ingestion like arsenic can? The answer to this is not so clear, but a recent publication by Beaumont et al. (6) concerning a study in the Liaoning Province in China documents increased cancer risks following ingestion of CrVI in drinking water: In particular, increased stomach cancer risks were demonstrated, but some evidence also indicated increased lung cancer risks. The cancer evidence from the population exposed in China first appeared more than 25 years ago.

In 1959, production of ferrochromium commenced in a factory in Liaoning Province, China (6,64,84). In 1964, residents living near the factory reported a yellow coloration in nearby wells used for drinking water, and in 1965, high concentrations of CrVI were confirmed and remediation work commenced; declines in concentrations of chromium in ground water were documented in 1967. Twenty years later, in 1987, Zhang & Li (90) published a paper in the *Chinese Journal of Preventive Medicine*, reporting increased stomach and lung cancer rates in the exposed villages. An unfortunate sequence of events followed, including publication by the same authors of an article in the *Journal of Occupational and Environmental Medicine (JOEM)* concluding that the results did not indicate an association of cancer mortality with exposure (89). Evidence emerged later that this paper involved a U.S. consulting firm that had been hired by industry clients with liability for chromium pollution in the United States (19). In 2006, nine years after the article had been published, the editor of *JOEM* retracted the paper, stating that “financial and intellectual input to the paper by outside parties was not disclosed” (8).

The recent publication by Beaumont et al. (6) presents findings from the same chromiumexposed population in China (6). They found that stomach cancer mortality in the exposed population was elevated compared with regions without contaminated water (RR = 1.82; CI 1.11--2.91) and compared with the whole province (RR = 1.69; CI 1.12--2.44). Lung cancer was not much increased in comparison with the unexposed regions (RR = 1.15; CI 0.62--2.07) but was increased in comparison with the whole province (RR = 1.78; CI 1.03--2.87). The study had some rather severe limitations described by the authors; these limitations included lack of information on mortality year by year so trends could be examined and lack of knowledge as to how the original authors had determined the deceased's places of residence (6). Perhaps the greatest weakness of the evidence was the short latency from exposure to increased mortality risks (64). The exposures may have started as early as 1960, but mortality was assessed for 1970--1978, concerning only 10--18 years from the time of first exposure. Yet the findings concerning stomach cancer at least seem consistent with the indication of increased risk. This study is important because the world may have no other population large enough in which to study high exposures of CrVI in water (64). It provides

human evidence on its own but with serious limitations. It is noteworthy, however, that animal ingestion studies also find carcinogenic effects of CrVI in water (58).

In summary, new epidemiological studies concerning chromium are lacking. However, the mortality study in China provides fascinating evidence that human ingestion of CrVI may increase the risk of stomach cancer.

ACKNOWLEDGEMENTS

Chiron Alston and Jane Liaw assisted in the preparation of this paper. Primary funding for this article was provided by the National Institutes of Health grants P42-ES04705, R01-HL081520, R01-ES014032.

LITERATURE CITED

- Ahmad SA, Khatun F, Sayed MH, Khan MH, Aziz R, et al. Electrocardiographic abnormalities among arsenic-exposed persons through groundwater in Bangladesh. *J. Health Popul. Nutr* 2006;24:221–27. [PubMed: 17195563]
- Ahmad SA, Sayed MH, Barua S, Khan MH, Faruquee MH, et al. Arsenic in drinking water and pregnancy outcomes. *Environ. Health Perspect* 2001;109:629–31. [PubMed: 11445518]
- Ahsan H, Chen Y, Kibriya MG, Slavkovich V, Parvez F, et al. Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. *Cancer Epidemiol. Biomarkers Prev* 2007;16:1270–78. [PubMed: 17548696]
- Ahsan H, Chen Y, Parvez F, Zablotska L, Argos M, et al. Arsenic exposure from drinking water and risk of premalignant skin lesions in Bangladesh: baseline results from the Health Effects of Arsenic Longitudinal Study. *Am. J. Epidemiol* 2006;163:1138–48. [PubMed: 16624965]
- Ahsan H, Perrin M, Rahman A, Parvez F, Stute M, et al. Associations between drinking water and urinary arsenic levels and skin lesions in Bangladesh. *J. Occup. Environ. Med* 2000;42:1195–201. [PubMed: 11125683]
- Beaumont JJ, Sedman RM, Reynolds SD, Sherman CD, Li LH, et al. Cancer mortality in a Chinese population exposed to hexavalent chromium in drinking water. *Epidemiology* 2008;19:12–23. [PubMed: 18091413]
- Borzsonyi M, Bereczky A, Rudnai P, Csanady M, Horvath A. Epidemiological studies on human subjects exposed to arsenic in drinking water in southeast Hungary. *Arch. Toxicol* 1992;66:77–78. [PubMed: 1580796]
- Brandt-Rauf P. Editorial retraction. Cancer mortality in a Chinese population exposed to hexavalent chromium in water. *J. Occup. Environ. Med* 2006;48:749. [PubMed: 16832233]
- Buchet JP, Lauwerys R, Roels H. Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. *Int. Arch. Occup. Environ. Health* 1981;48:71–79. [PubMed: 6894292]
- Chakraborty AK, Saha KC. Arsenical dermatosis from tubewell water in West Bengal. *Indian J. Med. Res* 1987;85:326–34. [PubMed: 2956191]
- Chen Y, Factor-Litvak P, Howe GR, Graziano JH, Brandt-Rauf P, et al. Arsenic exposure from drinking water, dietary intakes of B vitamins and folate, and risk of high blood pressure in Bangladesh: a population-based, cross-sectional study. *Am. J. Epidemiol* 2007;165:541–52. [PubMed: 17164464]
- Chen Y, Hakim ME, Parvez F, Islam T, Rahman AM, Ahsan H. Arsenic exposure from drinking-water and carotid artery intima-medial thickness in healthy young adults in Bangladesh. *J. Health Popul. Nutr* 2006;24:253–57. [PubMed: 17195567]
- Chen YC, Guo YL, Su HJ, Hsueh YM, Smith TJ, et al. Arsenic methylation and skin cancer risk in southwestern Taiwan. *J. Occup. Environ. Med* 2003;45:241–28. [PubMed: 12661181]
- Chen YC, Su HJ, Guo YL, Hsueh YM, Smith TJ, et al. Arsenic methylation and bladder cancer risk in Taiwan. *Cancer Causes Control* 2003;14:303–10. [PubMed: 12846360]

15. Chiu HF, Lin MC, Yang CY. Primary intracerebral hemorrhage mortality reduction after installation of a tap-water supply system in an arseniasis-endemic area in southwestern Taiwan. *J. Toxicol. Environ. Health A* 2007;70:539–46. [PubMed: 17365607]
16. Christian WJ, Hopenhayn C, Centeno JA, Todorov T. Distribution of urinary selenium and arsenic among pregnant women exposed to arsenic in drinking water. *Environ. Res* 2006;100:115–22. [PubMed: 16337848]
17. Concha G, Vogler G, Nermell B, Vahter M. Intra-individual variation in the metabolism of inorganic arsenic. *Int. Arch. Occup. Environ. Health* 2002;75:576–80. [PubMed: 12373320]
18. Cullen W, Reimer K. Arsenic speciation in the environment. *Chem. Rev* 1989;89:713–64.
19. Egilman D, Scout. Corporate corruption of science---the case of chromium(VI). *Int. J. Occup. Environ. Health* 2006;12:169–76. [PubMed: 16722197]
20. Engel RR, Hopenhayn-Rich C, Receveur O, Smith AH. Vascular effects of chronic arsenic exposure: a review. *Epidemiol. Rev* 1994;16:184–209. [PubMed: 7713176]
21. Enterline PE, Henderson VL, Marsh GM. Exposure to arsenic and respiratory cancer. A reanalysis. *Am. J. Epidemiol* 1987;125:929–38. [PubMed: 3578251]
22. Gamble MV, Liu X, Slavkovich V, Pilsner JR, Ilievski V, et al. Folic acid supplementation lowers blood arsenic. *Am. J. Clin. Nutr* 2007;86:1202–9. [PubMed: 17921403]
23. Gebel TW. Arsenic methylation is a process of detoxification through accelerated excretion. *Int. J. Hyg. Environ. Health* 2002;205:505–8. [PubMed: 12455273]
24. Ghosh P, Banerjee M, De Chaudhuri S, Chowdhury R, Das JK, et al. Comparison of health effects between individuals with and without skin lesions in the population exposed to arsenic through drinking water in West Bengal, India. *J. Expo. Sci. Environ. Epidemiol* 2007;17:215–23. [PubMed: 16835595]
25. Guha Mazumder DN, Haque R, Ghosh N, De BK, Santra A, et al. Arsenic levels in drinking water and the prevalence of skin lesions in West Bengal, India. *Int. J. Epidemiol* 1998;27:871–77. [PubMed: 9839746]
26. Haque R, Mazumder DN, Samanta S, Ghosh N, Kalman D, et al. Arsenic in drinking water and skin lesions: dose-response data from West Bengal, India. *Epidemiology* 2003;14:174–82. [PubMed: 12606883]
27. Heck JE, Chen Y, Grann VR, Slavkovich V, Parvez F, Ahsan H. Arsenic exposure and anemia in Bangladesh: a population-based study. *J. Occup. Environ. Med* 2008;50:80–87. [PubMed: 18188085]
28. Hopenhayn C, Ferreccio C, Browning SR, Huang B, Peralta C, et al. Arsenic exposure from drinking water and birth weight. *Epidemiology* 2003;14:593–602. [PubMed: 14501275]
29. Hopenhayn-Rich C, Browning SR, Hertz-Picciotto I, Ferreccio C, Peralta C, Gibb H. Chronic arsenic exposure and risk of infant mortality in two areas of Chile. *Environ. Health Perspect* 2000;108:667–73. [PubMed: 10903622]
30. Hopenhayn-Rich C, Smith AH, Goeden HM. Human studies do not support the methylation threshold hypothesis for the toxicity of inorganic arsenic. *Environ. Res* 1993;60:161–77. [PubMed: 8472646]
31. Hsueh YM, Chiou HY, Huang YL, Wu WL, Huang CC, et al. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. *Cancer Epidemiol. Biomarkers Prev* 1997;6:589–96. [PubMed: 9264271]
32. Huang YK, Huang YL, Hsueh YM, Yang MH, Wu MM, et al. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study. *Cancer Causes Control* 2008;19:829–39. [PubMed: 18351295]
33. Huang YK, Tseng CH, Huang YL, Yang MH, Chen CJ, Hsueh YM. Arsenic methylation capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in southwestern Taiwan. *Toxicol. Appl. Pharmacol* 2007;218:135–42. [PubMed: 17173945]
34. Huyck KL, Kile ML, Mahiuddin G, Quamruzzaman Q, Rahman M, et al. Maternal arsenic exposure associated with low birth weight in Bangladesh. *J. Occup. Environ. Med* 2007;49:1097–104. [PubMed: 18000415]
35. Infante-Rivard C, Olson E, Jacques L, Ayotte P. Drinking water contaminants and childhood leukemia. *Epidemiology* 2001;12:13–19. [PubMed: 11138808]

36. Int. Agency Res. Cancer (IARC). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Chromium, Nickel, and Welding. IARC; Lyon: 1990. Chromium and chromium compounds.
37. Kwok RK, Kaufmann RB, Jakariya M. Arsenic in drinking-water and reproductive health outcomes: a study of participants in the Bangladesh Integrated Nutrition Programme. *J. Health Popul. Nutr* 2006;24:190–205. [PubMed: 17195560]
38. Kwok RK, Mendola P, Liu ZY, Savitz DA, Heiss G, et al. Drinking water arsenic exposure and blood pressure in healthy women of reproductive age in Inner Mongolia, China. *Toxicol. Appl. Pharmacol* 2007;222:337–43. [PubMed: 17509635]
39. Lee-Feldstein A. Cumulative exposure to arsenic and its relationship to respiratory cancer among copper smelter employees. *J. Occup. Med* 1986;28:296–302. [PubMed: 3701479]
40. Liaw J, Marshall G, Yuan Y, Ferreccio C, Steinmaus C, Smith AH. Increased childhood liver cancer mortality and arsenic in drinking water in Northern Chile. *Cancer Epidemiol. Biomarkers Prev* 2008;17:1982–87. [PubMed: 18708388]
41. Lindberg AL, Rahman M, Persson LA, Vahter M. The risk of arsenic induced skin lesions in Bangladeshi men and women is affected by arsenic metabolism and the age at first exposure. *Toxicol. Appl. Pharmacol* 2008;1:9–16. [PubMed: 18336856]
42. Maharjan M, Watanabe C, Ahmad SA, Ohtsuka R. Arsenic contamination in drinking water and skin manifestations in lowland Nepal: the first community-based survey. *Am. J. Trop. Med. Hyg* 2005;73:477–79. [PubMed: 16103627]
43. Maki-Paakkanen J, Kurttio P, Paldy A, Pekkanen J. Association between the clastogenic effect in peripheral lymphocytes and human exposure to arsenic through drinking water. *Environ. Mol. Mutagen* 1998;32:301–13. [PubMed: 9882004]
44. Marafante E, Vahter M. The effect of methyltransferase inhibition on the metabolism of [74As] arsenite in mice and rabbits. *Chem. Biol. Interact* 1984;50:49–57. [PubMed: 6733804]
45. Marafante E, Vahter M, Envall J. The role of the methylation in the detoxication of arsenate in the rabbit. *Chem. Biol. Interact* 1985;56:225–38. [PubMed: 4075449]
46. Marshall G, Ferreccio C, Yuan Y, Bates M, Steinmaus C, et al. Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. *J. Natl. Cancer Inst* 2007;99:920–28. [PubMed: 17565158]
47. Mass MJ, Tennant A, Roop BC, Cullen WR, Styblo M, et al. Methylated trivalent arsenic species are genotoxic. *Chem. Res. Toxicol* 2001;14:355–61. [PubMed: 11304123]
48. McCarty KM, Chen YC, Quamruzzaman Q, Rahman M, Mahiuddin G, et al. Arsenic methylation, GSTT1, GSTM1, GSTP1 polymorphisms, and skin lesions. *Environ. Health Perspect* 2007;115:341–45. [PubMed: 17431481]
49. McDonald C, Hoque R, Huda N, Cherry N. Risk of arsenic-related skin lesions in Bangladeshi villages at relatively low exposure: a report from Gonoshasthaya Kendra. *Bull. World Health Organ* 2007;85:668–73. [PubMed: 18026622]
50. Meliker JR, Wahl RL, Cameron LL, Nriagu JO. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. *Environ. Health* 2007;6:4. [PubMed: 17274811]
51. Milton AH, Smith WP, Rahman B, Hasan Z, Kulsum Z, et al. Chronic arsenic exposure and adverse pregnancy outcomes in Bangladesh. *Epidemiology* 2005;16:82–86. [PubMed: 15613949]
52. Moore LE, Lu ML, Smith AH. Childhood cancer incidence and arsenic exposure in drinking water in Nevada. *Arch. Environ. Health* 2002;57:201–6. [PubMed: 12507173]
53. Moore MM, Harrington-Brock K, Doerr CL. Relative genotoxic potency of arsenic and its methylated metabolites. *Mutat. Res* 1997;386:279–90. [PubMed: 9219565]
54. Mumford JL, Wu K, Xia Y, Kwok R, Yang Z, et al. Chronic arsenic exposure and cardiac repolarization abnormalities with QT interval prolongation in a population-based study. *Environ. Health Perspect* 2007;115:690–94. [PubMed: 17520054]
- 54a. Natl. Toxicol. Progr. Dep. Health Hum. Serv.. Rep. NTP: TR-546. Research Triangle Park, NC: 2007. Toxicology and carcinogenesis studies of sodium dichromate dihydrate (CAS No. 7789-12-0) in F344/N rats and B6C3F1 mice (drinking water studies).

55. Natl. Res. Council. (NRC). Arsenic in Drinking Water. Natl. Acad. Press; Washington, DC: 1999. p. xvii-310.
56. Navas-Acien A, Sharrett AR, Silbergeld EK, Schwartz BS, Nachman KE, et al. Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. *Am. J. Epidemiol* 2005;162:1037-49. [PubMed: 16269585]
57. Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Vasken Aposhian H. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. *Toxicol. Appl. Pharmacol* 2000;163:203-7. [PubMed: 10698679]
58. Deleted in proof
59. Pu YS, Yang SM, Huang YK, Chung CJ, Huang SK, et al. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. *Toxicol. Appl. Pharmacol* 2007;218:99-106. [PubMed: 17196235]
60. Rahman A, Vahter M, Ekstrom EC, Rahman M, Golam Mustafa AH, et al. Association of arsenic exposure during pregnancy with fetal loss and infant death: a cohort study in Bangladesh. *Am. J. Epidemiol* 2007;165:1389-96. [PubMed: 17351293]
61. Rahman M, Vahter M, Sohel N, Yunus M, Wahed MA, et al. Arsenic exposure and age and sex-specific risk for skin lesions: a population-based case-referent study in Bangladesh. *Environ. Health Perspect* 2006;114:1847-52. [PubMed: 17185274]
62. Rahman M, Vahter M, Wahed MA, Sohel N, Yunus M, et al. Prevalence of arsenic exposure and skin lesions. A population based survey in Matlab, Bangladesh. *J. Epidemiol. Community Health* 2006;60:242-48. [PubMed: 16476755]
63. Siripitayakunkit, U.; Lue, S.; Choprapawon, C. Possible effects of arsenic on visual perception and visual-motor integration of children in Thailand. In: Chappell, WR.; Abernathy, CO.; Calderon, RL., editors. *Arsenic Exposure and Health Effects IV*. Elsevier; New York: 2001. p. 165-72.
64. Smith AH. Hexavalent chromium, yellow water, and cancer: a convoluted saga. *Epidemiology* 2008;19:24-26. [PubMed: 18091414]
65. Smith AH, Goycolea M, Haque R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. *Am. J. Epidemiol* 1998;147:660-69. [PubMed: 9554605]
66. Smith AH, Marshall G, Yuan Y, Ferreccio C, Liaw J, et al. Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. *Environ. Health Perspect* 2006;114:1293-96. [PubMed: 16882542]
- 66a. Srivastava S, D'Souza SE, Sen U, States JC. *In utero* arsenic exposure induces early onset of atherosclerosis in ApoE^{-/-} mice. *Reprod. Toxicol* 2007;23:449-56. [PubMed: 17317095]
67. Steinmaus C, Bates MN, Yuan Y, Kalman D, Atallah R, et al. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. *J. Occup. Environ. Med* 2006;48:478-88. [PubMed: 16688004]
68. Steinmaus C, Moore LE, Shipp M, Kalman D, Rey OA, et al. Genetic polymorphisms in MTHFR 677 and 1298, GSTM1 and T1, and metabolism of arsenic. *J. Toxicol. Environ. Health A* 2007;70:159-70. [PubMed: 17365577]
69. Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH. Intraindividual variability in arsenic methylation in a U.S. population. *Cancer Epidemiol. Biomarkers Prev* 2005;14:919-24. [PubMed: 15824164]
70. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, et al. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. *Arch. Toxicol* 2000;74:289-99. [PubMed: 11005674]
71. Tondel M, Rahman M, Magnuson A, Chowdhury IA, Faruquee MH, Ahmad SA. The relationship of arsenic levels in drinking water and the prevalence rate of skin lesions in Bangladesh. *Environ. Health Perspect* 1999;107:727-29. [PubMed: 10464073]
72. Tsai SY, Chou HY, The HW, Chen CM, Chen CJ. The effects of chronic arsenic exposure from drinking water on the neurobehavioral development in adolescence. *Neurotoxicology* 2003;24:747-53. [PubMed: 12900089]

73. Tseng CH, Huang YK, Huang YL, Chung CJ, Yang MH, et al. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. *Toxicol. Appl. Pharmacol* 2005;206:299–308. [PubMed: 16039941]
74. Tseng WP, Chu HM, How SW, Fong JM, Lin CS, Yeh SJ. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. *J. Natl. Cancer Inst* 1968;40:453–63. [PubMed: 5644201]
75. Vahter M. Mechanisms of arsenic biotransformation. *Toxicology* 2002;181–182:211–7. [PubMed: 12505313]
76. Vahter M. Health effects of early life exposure to arsenic. *Basic Clin. Pharmacol. Toxicol* 2008;102:204–11. [PubMed: 18226075]
77. Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG, Cruz-Gonzalez MB, Garcia-Montalvo EA, et al. Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. *Environ. Health Perspect* 2005;113:250–54. [PubMed: 15743710]
78. von Ehrenstein OS, Guha Mazumder DN, Hira-Smith M, Ghosh N, Yuan Y, et al. Pregnancy outcomes, infant mortality, and arsenic in drinking water in West Bengal, India. *Am. J. Epidemiol* 2006;163:662–69. [PubMed: 16524957]
79. von Ehrenstein OS, Poddar S, Yuan Y, Mazumder DG, Eskenazi B, et al. Children's intellectual function in relation to arsenic exposure. *Epidemiology* 2007;18:44–51. [PubMed: 17149142]
80. Waalkes MP, Keefer LK, Diwan BA. Induction of proliferative lesions of the uterus, testes, and liver in swiss mice given repeated injections of sodium arsenate: possible estrogenic mode of action. *Toxicol. Appl. Pharmacol* 2000;166:24–35. [PubMed: 10873715]
81. Waalkes MP, Liu J, Diwan BA. Transplacental arsenic carcinogenesis in mice. *Toxicol. Appl. Pharmacol* 2007;222:271–80. [PubMed: 17306315]
82. Wang CH, Hsiao CK, Chen CL, Hsu LI, Chiou HY, et al. A review of the epidemiologic literature on the role of environmental arsenic exposure and cardiovascular diseases. *Toxicol. Appl. Pharmacol* 2007;222:315–26. [PubMed: 17433393]
83. Wasserman GA, Liu X, Parvez F, Ahsan H, Factor-Litvak P, et al. Water arsenic exposure and children's intellectual function in Araihaazar, Bangladesh. *Environ. Health Perspect* 2004;112:1329–33. [PubMed: 15345348]
84. Wilcox AJ, Savitz DA, Samet JM. A tale of two toxicants: lessons from Minamata and Liaoning. *Epidemiology* 2008;19:1–2. [PubMed: 18091410]
85. Wu MM, Chiou HY, Hsueh YM, Hong CT, Su CL, et al. Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis. *Toxicol. Appl. Pharmacol* 2006;216:168–75. [PubMed: 16806340]
86. Yang CY, Chang CC, Tsai SS, Chuang HY, Ho CK, Wu TN. Arsenic in drinking water and adverse pregnancy outcome in an arseniasis-endemic area in northeastern Taiwan. *Environ. Res* 2003;91:29–34. [PubMed: 12550085]
87. Yu RC, Hsu KH, Chen CJ, Froines JR. Arsenic methylation capacity and skin cancer. *Cancer Epidemiol. Biomarkers Prev* 2000;9:1259–62. [PubMed: 11097236]
88. Yuan Y, Marshall G, Ferreccio C, Steinmaus C, Selvin S, et al. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. *Am. J. Epidemiol* 2007;166:1381–91. [PubMed: 17875584]
89. Zhang JD, Li S. Cancer mortality in a Chinese population exposed to hexavalent chromium in water. *J. Occup. Environ. Med* 1997;39:315–19. [PubMed: 9113601]
90. Zhang JD, Li XL. Chromium pollution of soil and water in Jinzhou. *Zhonghua Yu Fang Yi Xue Za Zhi* 1987;21:262–64. [PubMed: 3443034]




Figure 1. Odds ratios of various arsenic-related health effects in people who excrete high and low proportions of arsenic in their urine as MA (%MMA).

Table 1

Studies concerning the health consequences of early life exposure to arsenic in drinking water

Study/author	Publication year	Population Studied	Arsenic concentration ^a	Findings
Pregnancy outcomes				
Borzsonyi et al. (7)	1992	Hungary	170--330 µg/L	Increase in stillbirths and spontaneous abortion
Hopenhayn-Rich et al. (29)	2000	Chile	860 µg/L	Increase in stillbirths and infant mortality
Ahmad et al. (2)	2001	Bangladesh	100+ µg/L	Increase in spontaneous abortions, stillbirths, and preterm births
Hopenhayn et al. (28)	2003	Chile	Up to 50 µg/L	Reduced birth weight
Yang et al. (86)	2003	Taiwan	Up to 3590 µg/L	Reduced birth weight
Milton et al. (51)	2005	Bangladesh	Average 279 µg/L	Increase in spontaneous abortion and stillbirths
Kwok et al. (37)	2006	Bangladesh	300+ µg/L	No increase in stillbirth or low birth weight
von Ehrenstein et al. (78)	2006	India	200+ µg/L	Increase in stillbirths not in spontaneous abortions
Huyck et al. (34)	2007	Bangladesh	Up to 734 µg/L	Reduced birth weight
Rahman et al. (60)	2007	Bangladesh	500+ µg/L	Minor increase in fetal loss and infant mortality
Child cognitive function				
Siripitayakunkit et al. (63)	2001	Thailand	Not clear ^b	Impaired visual perception
Tsai et al. (72)	2003	Taiwan	Average 185 µg/L	Reduced pattern memory and switching attention
Wasserman et al. (83)	2004	Bangladesh	Up to 790 µg/L	Reduction in some performance and full-scale scores tests
von Ehrenstein et al. (79)	2007	India	100+ µg/L	Reduction in vocabulary, object assembly, and picture completion scores
Child cancer				
Moore et al. (52)	2002	United States	35--90 µg/L	Leukemia not increased, slight increase in some other cancers
Liaw et al. (40)	2008	Chile	Up to 860 µg/L	Increased liver cancer mortality for ages 10--19
Adult diseases following early life exposure				
Smith et al. (65)	1998	Chile	Up to 860 µg/L	Increased lung cancer and chronic obstructive pulmonary disease (COPD) deaths aged 30--39
Smith et al. (66)	2006	Chile	Up to 860 µg/L	Lung cancer/bronchiectasis deaths after in utero/child exposure
Yuan et al. (88)	2007	Chile	Up to 860 µg/L	Increased acute myocardial infarction deaths after in utero/child exposure
Lindberg et al. (41)	2008	Bangladesh	Average lifetime 181+ µg/L	Lower skin lesion risk if exposed in infancy

^aWhere possible, the highest arsenic exposure category is given.

^bArsenic measurements in hair were obtained, and the high exposure group had hair concentrations above 5 µg/g.

Table 2
Studies of arsenic concentrations in drinking water and skin lesion prevalence^a

Author	Publication Year	Population Studied	Number of cases with skin lesions	Range of As concentration $\mu\text{g/L}$	Number of skin lesion cases with exposure $<50 \mu\text{g/L}$	Percentage of cases with skin lesions with exposure $<50 \mu\text{g/L}$
Guha Mazumder (25)	1998	India	517	0--3400	12	2.3%
Tondel (71)	1999	Bangladesh	430	10--2040	37 ^b	8.6%
Ahsan (5)	2000	Bangladesh	36	<29 -991	13	36.1%
Haque (26)	2003	India	192	0--500	6	3.1%
Maharjan (42)	2005	Nepal	93	3--1072	Not given	Not given
Ahsan (4)	2006	Bangladesh	714	8--864	147 ^c	20.6%
Rahman (61,62)	2006	Bangladesh	504	0--3644	78	15.5%
Ghosh (24)	2007	India	373	50--1188	Not given	Not given
McDonald (49)	2007	Bangladesh	155	0--166	138	89.0%

^aCases reported to have been consuming water containing less than $50 \mu\text{g/L}$ of arsenic

^bAs exposure $<150 \mu\text{g/L}$

^cTime-weighted well arsenic concentration $<40 \mu\text{g/L}$

Table 3

Studies concerning cardiovascular consequences of early life exposure to arsenic in drinking water published since 2006

Study/author	Publication year	Population studied	Arsenic concentration	Findings
Ahmad et al. (1)	2006	Bangladesh	Average about 500 µg/L	Electrocardiogram abnormalities related to arsenic-induced skin lesions
Chen et al. (12)	2006	Bangladesh	Up to 864 µg/L	Increased pulse pressure with arsenic exposure
Wu et al. (85)	2006	Taiwan	Up to 3590 µg/L	Increased prevalence of carotid atherosclerosis
Chen et al. (11)	2007	Bangladesh	Up to 864 µg/L	Increased vascular inflammation
Chiu et al. (15)	2007	Taiwan	Up to 1140 µg/L	Intracerebral hemorrhage mortality reduced after exposure was reduced
Kwok et al. (38)	2007	China	100+ µg/L	Increased blood pressure
Meliker (50)	2007	USA	Average 11 µg/L	Cerebrovascular disease; both men and women, SMR =1.19
Mumford et al. (54)	2007	China	430–690 µg/L	Electrocardiogram abnormalities related to arsenic water concentrations
Yuan et al. (88)	2007	Chile	Up to 860 µg/L	Increased myocardial infarction but not cerebrovascular mortality
Heck et al. (27)	2008	Bangladesh	200+ µg/L	Increased anemia with high arsenic exposure

Table 4
Study descriptions and odds ratios of arsenic-related health effects comparing people with high and low %MMA^a

Author	Year	Country	Outcome	Low %MMA			High %MMA			Definition of high %MMA
				Odds ratio	Confidence interval	Odds ratio	Confidence interval	Odds ratio	Confidence interval	
Hsueh et al. (31)	1997	Taiwan	Skin cancer	1.00	Ref	2.87	Not available		%MMA > 26.7%	
Yu et al. (87)	2000	Taiwan	Skin cancer	1.00	Ref	5.50	1.22--24.81		%MMA > 15.5%	
Chen et al. (13)	2003	Taiwan	Skin cancer	1.89	0.60--6.01	7.48	1.65--33.99		MMA/DMA > 0.20	
Chen et al. (14)	2003	Taiwan	Bladder cancer	1.12	0.26--4.7	4.23	1.12--16.01		MMA/DMA > 0.21	
Tseng et al. (73)	2005	Taiwan	PVD	2.64	0.56--12.45	4.57	1.01--20.61		%MMA > 11.42%	
Steinmaus et al. (67)	2006	Argentina	Bladder cancer	1.00	Ref	2.17	1.02--4.63		%MMA > = 16.7%	
Steinmaus et al. (67)	2006	United States	Bladder cancer	1.00	Ref	2.70	0.39--18.6		%MMA > = 14.8%	
Wu et al. (85)	2006	Taiwan	Atherosclerosis	1.7	0.6--4.5	2.7	1.0--7.8		%MMA > = 13.4%	
Ahsan et al. (3)	2007	Bangladesh	Skin lesions	1.00	Ref	1.57	1.10--2.26		%MMA > 16.4%	
Huang et al. (33)	2007	Taiwan	Hypertension	1.00	Ref	1.04	0.66--1.62		%MMA > = 15.55%	
McCarty et al. (48)	2007	Bangladesh	Skin lesions	1.00	Ref	1.50	1.00--2.26		10X MMA/InAs	
Pu et al. (59)	2007	Taiwan	Bladder cancer	1.0	Ref	2.8	1.6--4.8		%MMA > 9.2%	
Huang et al. (32)	2008	Taiwan	Bladder cancer	1.5	0.4--5.9	3.7	1.2--11.6		%MMA > = 11.40%	
Lindberg et al. (41)	2008	Bangladesh	Skin lesions	1.0	Ref	2.8	1.9--4.2		%MMA > 12%	

^a Abbreviations: 10X MMA/InAs, tenfold increase in MMA/InAs ratio; CAE, cumulative arsenic exposure; PVD, peripheral vascular disease; Ref, reference group